The Third Time’s The Charm? Xbrane Resubmits Ranibizumab In US
Follows Two Previous Knockbacks From FDA Over Lucentis Biosimilar
Xbrane is taking a third shot at filing its ranibizumab biosimilar rival to Lucentis with the US Food and Drug Administration. Will it succeed where it has previously failed to gain approval?
